PSMB9

Across TCGA pan-cancer cohorts, PSMB9 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PSMB9 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PSMB9 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PSMB9 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where PSMB9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.887	0.283	.012	23	view →
PDAC	OS	Tertile	II,III,IV	0.773	0.439	.013	9	view →
LUAD	DFS	Median	III,IV	0.886	0.595	.014	4	view →
UCEC	OS	Tertile	All	1.000	0.923	.041	4	view →
HNSC	DFS	Median	II,III,IV	0.697	0.873	.025	3	view →
LSCC	OS	Quartile	II,III,IV	0.620	0.945	.019	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PSMB9–CCRCC (DFS)

Open the CCRCC breakdown →